Company intelligence / Profile preview
Imbioray
Hangzhou, Zhejiang Sheng, Chinaimbiorayhz.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Imbioray is advancing a pipeline of off-the-shelf, allogeneic CAR-NK and NK engager therapies targeting cancer. Lead assets IBR‑822, IBR‑733, and IBR854 are in Phase 1 clinical trials for various hematologic malignancies and solid tumors. The company has received IND approval for additional programs such as IBR900 targeting B-cell lymphoma. Recent funding rounds support clinical advancement and GMP manufacturing expansion.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-NK cell therapyCell therapyNon-genetically modified CAR-NK cell therapyNK cell engager cell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
T-Capital served as financial advisor in Series A financing round
Beyond the preview
Go deeper on Imbioray.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imbioray.